Mouse gene knockout models for the CLN2 and CLN3 forms of ceroid lipofuscinosis.
The childhood neuronal ceroid-lipofuscinoses (NCLs) are autosomal-recessively inherited neurodegenerative disorders that result in severe cognitive decline and premature death. The genetic bases for a number of different forms of NCL, including those designated CLN2 and CLN3, have now been determined. However, the mechanisms by which the gene defects cause the disease pathology are not known and no effective treatments for these disorders have been developed. To provide tools for studying the mechanisms underlying the disease pathologies and for screening potential therapeutic interventions, work is under way to develop mouse models for the CLN2 and CLN3 disorders. Targeted gene replacement was used to generate mice in which the murine orthologue of the CLN3 gene has been knocked out. Mice that are homozygous for the Cln3 knockout allele develop a number of pathological features similar to those that occur in the human disorder. Among these are accumulation of autofluorescent lysosomal storage bodies, behavioural abnormalities, retinal degeneration, and premature death. On a mixed strain genetic background, the appearance of these symptoms was quite variable, suggesting that other genes can modify the effects of CLN3 mutations. Work to develop a similar mouse gene knockout model for the CLN2 disorder is well under way. Chimaeric mice have been developed with cells that carry an induced mutation in the mouse orthologue of the CLN2 gene that would prevent synthesis of a functional CLN2 protein in mice that are homozygous for the mutation. Mice will be developed that are homozygous for this mutation, and these animals will be evaluated for the development of pathologies similar to those that occur in the human disorder.
Katz
M L
ML
Mason Eye Institute, Department of Veterinary Pathobiology, University of Missouri, School of Medicine, One Hospital Drive, Columbia, Missouri 65212, USA. katzm@health.missouri.edu
Johnson
G S
GS
D000626:Aminopeptidases; D000818:Animals; D002648:Child; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; D004195:Disease Models, Animal; D010450:Endopeptidases; D006801:Humans; D008247:Lysosomes / Q000201:enzymology / Q000648:ultrastructure; D008562:Membrane Glycoproteins; D051379:Mice; D018345:Mice, Knockout; D008854:Microscopy, Electron; D018832:Molecular Chaperones; D009410:Nerve Degeneration / Q000201:enzymology / Q000235:genetics; D009472:Neuronal Ceroid-Lipofuscinoses / Q000201:enzymology / Q000235:genetics*; D010447:Peptide Hydrolases / Q000235:genetics*; D010641:Phenotype; D011506:Proteins / Q000235:genetics*; D057057:Serine Proteases; D000091346:Tripeptidyl-Peptidase 1
C102229:CLN3 protein, mouse; D008562:Membrane Glycoproteins; D018832:Molecular Chaperones; D011506:Proteins; C000717268:Tpp1 protein, mouse; D000091346:Tripeptidyl-Peptidase 1; D010450:Endopeptidases; D010447:Peptide Hydrolases; D057057:Serine Proteases; D000626:Aminopeptidases; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases; C000717267:TPP1 protein, human